Literature DB >> 23959583

Diagnostic challenges in a case of B cell lymphoma unclassifiable with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma.

Chi-Chiu So, Ka-Hung Yung, Man-Leng Chu, Thomas S K Wan.   

Abstract

Unclassifiable B-cell lymphoma with features intermediate between diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL) is a recently recognized category of mature B-cell lymphoma. This represents a heterogeneous group of diseases which often pose diagnostic problems in clinical practice, yet its distinction from DLBCL to BL is important for its therapeutic and prognostic implications. We report the challenging diagnostic process of a 60-year-old man. He had a CD10 and BCL2-positive, BCL6-negative B-cell malignancy with loss of multiple B-cell markers including surface immunoglobulin. The karyotype was complex and unusual, including t(2;18)(p12;q21), t(8;14)(q24;q32) and a derivative chromosome 22 mimicking a Philadelphia chromosome that led to initial diagnostic confusion. A triple-hit gray zone B-cell lymphoma with rearrangements of MYC, BCL2, BCL6, both alleles of IGH and likely IGK and IGL was finally diagnosed upon additional fluorescence in situ hybridization (FISH) studies. His disease was nonresponsive to intensive combination chemotherapy and he died 4 months after presentation. This case illustrates the diagnostic difficulty encountered in such group of B-cell lymphomas and emphasizes the need to integrate morphological, immunophenotypic and genetic data in making a diagnosis.

Entities:  

Mesh:

Year:  2013        PMID: 23959583     DOI: 10.1007/s12185-013-1414-9

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  11 in total

Review 1.  Philadelphia-positive acute lymphoblastic leukemia: current treatment options.

Authors:  Theresa Liu-Dumlao; Hagop Kantarjian; Deborah A Thomas; Susan O'Brien; Farhad Ravandi
Journal:  Curr Oncol Rep       Date:  2012-10       Impact factor: 5.075

2.  Molecular diagnosis of Burkitt's lymphoma.

Authors:  Sandeep S Dave; Kai Fu; George W Wright; Lloyd T Lam; Philip Kluin; Evert-Jan Boerma; Timothy C Greiner; Dennis D Weisenburger; Andreas Rosenwald; German Ott; Hans-Konrad Müller-Hermelink; Randy D Gascoyne; Jan Delabie; Lisa M Rimsza; Rita M Braziel; Thomas M Grogan; Elias Campo; Elaine S Jaffe; Bhavana J Dave; Warren Sanger; Martin Bast; Julie M Vose; James O Armitage; Joseph M Connors; Erlend B Smeland; Stein Kvaloy; Harald Holte; Richard I Fisher; Thomas P Miller; Emilio Montserrat; Wyndham H Wilson; Manisha Bahl; Hong Zhao; Liming Yang; John Powell; Richard Simon; Wing C Chan; Louis M Staudt
Journal:  N Engl J Med       Date:  2006-06-08       Impact factor: 91.245

Review 3.  The gray zone between Burkitt's lymphoma and diffuse large B-cell lymphoma from a genetics perspective.

Authors:  Itziar Salaverria; Reiner Siebert
Journal:  J Clin Oncol       Date:  2011-04-11       Impact factor: 44.544

4.  A 14;18 and an 8;14 chromosome translocation in a cell line derived from an acute B-cell leukemia.

Authors:  L Pegoraro; A Palumbo; J Erikson; M Falda; B Giovanazzo; B S Emanuel; G Rovera; P C Nowell; C M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  1984-11       Impact factor: 11.205

5.  Common ALL with pre-B-cell features showing (8;14) and (14;18) chromosome translocations.

Authors:  G J Mufti; T J Hamblin; D G Oscier; S Johnson
Journal:  Blood       Date:  1983-11       Impact factor: 22.113

6.  A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling.

Authors:  Michael Hummel; Stefan Bentink; Hilmar Berger; Wolfram Klapper; Swen Wessendorf; Thomas F E Barth; Heinz-Wolfram Bernd; Sergio B Cogliatti; Judith Dierlamm; Alfred C Feller; Martin-Leo Hansmann; Eugenia Haralambieva; Lana Harder; Dirk Hasenclever; Michael Kühn; Dido Lenze; Peter Lichter; Jose Ignacio Martin-Subero; Peter Möller; Hans-Konrad Müller-Hermelink; German Ott; Reza M Parwaresch; Christiane Pott; Andreas Rosenwald; Maciej Rosolowski; Carsten Schwaenen; Benjamin Stürzenhofecker; Monika Szczepanowski; Heiko Trautmann; Hans-Heinrich Wacker; Rainer Spang; Markus Loeffler; Lorenz Trümper; Harald Stein; Reiner Siebert
Journal:  N Engl J Med       Date:  2006-06-08       Impact factor: 91.245

7.  Acute lymphoblastic leukemia with the (8;14)(q24;q32) translocation and FAB L3 morphology associated with a B-precursor immunophenotype: the Pediatric Oncology Group experience.

Authors:  F Navid; A D Mosijczuk; D R Head; M J Borowitz; A J Carroll; J M Brandt; M P Link; M K Rozans; G A Thomas; M R Schwenn; D J Shields; T J Vietti; D J Pullen
Journal:  Leukemia       Date:  1999-01       Impact factor: 11.528

Review 8.  Burkitt's leukemia with precursor B-cell immunophenotype and atypical morphology (atypical Burkitt's leukemia/lymphoma): case report and review of literature.

Authors:  Rami Komrokji; Jeffrey Lancet; Raymond Felgar; Nancy Wang; John M Bennett
Journal:  Leuk Res       Date:  2003-06       Impact factor: 3.156

9.  Novel lymphoid neoplasms--the borderland between diffuse large B-cell lymphoma and Burkitt's lymphoma.

Authors:  Daphne de Jong
Journal:  Haematologica       Date:  2009-07       Impact factor: 9.941

10.  B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and burkitt lymphoma: study of 39 cases.

Authors:  Anamarija M Perry; David Crockett; Bhavana J Dave; Pamela Althof; Lisa Winkler; Lynette M Smith; Patricia Aoun; Wing C Chan; Kai Fu; Timothy C Greiner; Phillip Bierman; Robert Gregory Bociek; Julie M Vose; James O Armitage; Dennis D Weisenburger
Journal:  Br J Haematol       Date:  2013-04-18       Impact factor: 6.998

View more
  2 in total

1.  Double- and triple-hit lymphomas can present with features suggestive of immaturity, including TdT expression, and create diagnostic challenges.

Authors:  Laura Moench; Zohar Sachs; Garth Aasen; Michelle Dolan; Vanessa Dayton; Elizabeth L Courville
Journal:  Leuk Lymphoma       Date:  2016-02-18

Review 2.  Cancer cytogenetics: methodology revisited.

Authors:  Thomas S K Wan
Journal:  Ann Lab Med       Date:  2014-10-28       Impact factor: 3.464

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.